A5080225846- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Immune Response and Inflammation
- Mesenchymal stem cell research
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 and COVID-19 Research
- Diabetes and associated disorders
- Hepatitis B Virus Studies
- Long-Term Effects of COVID-19
- Cytokine Signaling Pathways and Interactions
- Bacterial Infections and Vaccines
- Dysphagia Assessment and Management
- Reproductive System and Pregnancy
- Animal Virus Infections Studies
- Hematopoietic Stem Cell Transplantation
- Systemic Lupus Erythematosus Research
- SARS-CoV-2 detection and testing
- IL-33, ST2, and ILC Pathways
- Escherichia coli research studies
- Cytomegalovirus and herpesvirus research
- Esophageal and GI Pathology
- Tracheal and airway disorders
National Academy of Sciences of Belarus
2020-2024
Institute of Biophysics and Cell Engineering
2020-2024
Montana State University
2005-2010
Dartmouth College
2009
Adoptive transfer of T cells expressing chimeric NKG2D (chNKG2D) receptors, a fusion and CD3zeta, can lead to long-term, tumor-free survival in murine model ovarian cancer. To determine the mechanisms chNKG2D cell antitumor efficacy, we analyzed how altered tumor microenvironment, including tumor-infiltrating leukocyte populations. treatment mice bearing ID8 increased number activation NK host CD8+ within tumor. Foxp3+ regulatory at site decreased more than 300-fold after treatment....
Abstract Treatment with an anti-inflammatory Salmonella vaccine expressing enterotoxigenic Escherichia coli colonization factor Ag 1 (CFA/I) proved effective in stimulating protective, potent CD25+CD4+ regulatory T (Treg) cells susceptible mice challenged experimental autoimmune encephalomyelitis (EAE). Because the vector was considerably less we questioned whether altering fimbrial subunit expression to resemble conventional may impact Treg cell potency. The Salmonella-CFA/I modified limit...
Abstract Regulatory T (Treg) cells show promise for treating autoimmune diseases, but their induction to elevated potency has been problematic when the most optimally derived are from diseased animals. To circumvent reliance on autoantigen-reactive Treg cells, stimulation myelin-independent Ags may offer a viable alternative while maintaining treat experimental encephalomyelitis (EAE). The Salmonella vaccine expressing colonization factor Ag I possesses anti-inflammatory properties and,...
Abstract Mucosal tolerance induction generally requires multiple or large Ag doses. Because microfold (M) cells have been implicated as being important for mucosal and because reovirus attachment protein σ1 (pσ1) is capable of binding M cells, we postulated that targeting a model to via pσ1 could induce state unresponsiveness. Accordingly, genetic fusion between OVA the cell ligand, pσ1, termed OVA-pσ1, was developed enhance tolerogen uptake. When applied nasally, not parenterally, little...
Abstract An experimental vaccine for enterotoxigenic Escherichia coli (ETEC) composed of a live, attenuated Salmonella vector-expressing E. fimbriae, colonization factor Ag I (CFA/I), stimulated biphasic Th cell response when given orally and suppressed the normally produced proinflammatory response. Such suppression was also evident upon Salmonella-CFA/I infection macrophages resulting in diminished TNF-α, IL-1, IL-6 production suggesting that CFA/I fimbrial expression by may protect...
Conventional methods to induce tolerance in humans have met with limited success. Hence, efforts redirect tolerogen uptake using reovirus adhesin, protein sigma 1 (pσ1), may circumvent these shortcomings based upon the recent finding that when pσ1 is engineered deliver chicken ovalbumin (OVA) mucosally, obtained, even a single dose. To test whether single-dose can be induced treat EAE, proteolipid (PLP130–151) was genetically fused OVA (PLP:OVA-pσ1) and shown significantly ameliorate...
Objective. To determine the effect of pooling (merging) single cultures olfactory mucosa-derived mesenchymal stem cells (MSCs) nasal cavity on suppression proliferative activity T-lymphocytes. Materials and methods. Using flow cytometry, MSCs obtained from healthy donors (n=7) mitogen-induced proliferation T-lymphocytes in peripheral blood volunteers (n=5) was studied. The index number dividing CD3 + T-cells were assessed by changes fluorescence intensity Tag-it Vio. Statistical processing...
Laryngotracheal stenosis is a serious pathological process that leads to the narrowing of airways because damage mucous membrane and formation pathophysiological mechanisms regeneration. Mesenchymal stem cells (MSCs) are known be able suppress inflammatory response stimulate tissue regeneration; why, they promising biomedical cell product for treatment laryngotracheal stenosis. The aim this study was evaluate safety, tolerability, long-term clinical efficacy therapy using autologous MSCs...
An important place in the pathogenesis of systemic lupus erythematosus (SLE) is given to immune mechanisms, many aspects which, despite intensive study, remain unclear. As a result activation T and B cells, production antibodies (including autoantibodies) increases, hypergammaglobulinemia occurs, complexes are formed. The use mesenchymal stem cells (MSCs) as basis biomedical cell product for SLE therapy justified due fact that this type has wide immunomodulatory activity range. In recent...
Background. The difficulty in diagnosing COVID-19 is associated with the heterogeneity of clinical manifestations, and treatment difficult because course disease varies from asymptomatic to severe viral pneumonia, a cytokine storm development acute respiratory distress syndrome (ARDS). Certain hopes ARDS are currently pinned on use mesenchymal stem cells (MSCs), due their ability influence immune system activate regeneration damaged tissues. aim study was improve efficacy existing methods...
Abstract Reovirus protein sigma 1 (pσ1), engineered to deliver OVA mucosally, induced tolerance in mice even with a single, low dose. To test the efficacy of pσ1-based therapy, extracellular domain myelin oligodendrocyte glycoprotein (MOG29-146) was genetically fused pσ1 (MOG-pσ1). Susceptible C57BL/6 were nasally dosed PBS, MOG-pσ1, or recombinant (r)MOG and 3 wks later challenged MOG35-55-induced EAE. not rMOG abrogated EAE incidence evidenced by >8-fold reductions IFN-γ, IL-17,...
Recently it was shown that when reovirus protein sigma 1 (pσ1) is engineered to deliver ovalbumin (OVA) mucosally, tolerance obtained, even with a single dose. To test whether pσ1‐based tolerogen can prevent and/or treat autoimmune disease, genetic fusion between proteolipid (PLP) peptide, PLP 130–159 and OVA‐pσ1, termed AR1, produced used nasally dose EAE‐susceptible SJL/J mice in prophylactic or therapeutic paradigm. In either case, clinical EAE histology of spinal cords greatly reduced...